Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
2 registry-linked trialsAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 224 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
224citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study.
NCT06599216 phase2active not recruitingnot on this mapstarted 2024, after this paper: background citation
Adebrelimab Combined With Dalpicicliband Standard Endocrine Therapy for HR + / HER 2-breast Cancer:A Single-center,Open-label,Single-arm Clinical Trial
Who cites it
224 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.Current oncology (Toronto, Ont.) · 2026Guideline
- Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015).Nature communications · 2026Trial
- Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.Nature communications · 2026Trial
- Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.Nature communications · 2026Trial
- Trial
- Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study.Nature communications · 2025Trial
- Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.Endocrine-related cancer · 2025Trial
- Trial
- Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study.Breast cancer research : BCR · 2025Trial
- A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.The oncologist · 2024Trial
- Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer.Breast cancer research and treatment · 2023Trial
- CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).Breast cancer research : BCR · 2023Trial
- A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.Breast cancer research and treatment · 2023Trial
- Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.The Lancet. Oncology · 2023Trial
- Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
164 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Cynthia X MaDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri. cynthiaxma@wustl.edu mjellis@bcm.edu.
Feng GaoDivision of Public Health Science, Siteman Cancer Center Biostatistics Core, Washington University School of Medicine, St. Louis, Missouri.
Jingqin LuoDivision of Public Health Science, Siteman Cancer Center Biostatistics Core, Washington University School of Medicine, St. Louis, Missouri.
Donald W NorthfeltDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona.
Matthew GoetzDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Andres ForeroDepartment of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Jeremy HoogDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Michael NaughtonDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Foluso AdemuyiwaDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Rama SureshDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Karen S AndersonDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona.
Julie MargenthalerSection of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Rebecca AftSection of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Timothy HobdayDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Timothy MoynihanDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
William GillandersSection of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Amy CyrSection of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Timothy J EberleinSection of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Tina HiekenDepartment of Surgery, Mayo Clinic, Rochester, Minnesota.
Helen KrontirasDepartment of Surgery, University of Alabama at Birmingham, Birmingham, Alabama.
Zhanfang GuoDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Michelle V LeeDepartment of Radiology, Washington University School of Medicine, St. Louis, Missouri.
Nicholas C SpiesMcDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri.
Zachary L SkidmoreMcDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri.
Obi L GriffithDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Malachi GriffithMcDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri.
Shana ThomasDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Caroline BumbDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Kiran VijDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Cynthia Huang BartlettPfizer Pharmaceuticals, New York, New York.
Maria KoehlerPfizer Pharmaceuticals, New York, New York.
Hussam Al-KatebDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
Souzan SanatiDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
Matthew J EllisLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. cynthiaxma@wustl.edu mjellis@bcm.edu.
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MNOVEL BIOMARKERS FOR AROMATASE INHIBITOR THERAPYR01CA095614 · NCI · WASHINGTON UNIVERSITY · PI ELLIS, MATTHEW J, LUO, JINGQIN · 2003 to 2013
$5.6MIntegrated Analysis & Interpretation of Whole Genome Exome & Transcriptome SequenR00HG007940 · NHGRI · WASHINGTON UNIVERSITY · PI GRIFFITH, MALACHI · 2017 to 2019
$724kDEFINING THE REGULATORY, NON-CODING, MUTATIONAL LANDSCAPE OF BREAST CANCERK22CA188163 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2014 to 2016
$515kNCI NIH HHS K22 CA188163NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA095614NHGRI NIH HHS R00 HG007940
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAnastrozoleAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCell ProliferationClass I Phosphatidylinositol 3-KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Disease-Free SurvivalErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedAnastrozoleCDK6 protein, humanClass I Phosphatidylinositol 3-KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesESR1 protein, humanEstrogen Receptor alphaNitrilespalbociclibPIK3CA protein, humanPiperazinesPyridinesTriazoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05163106ClinicalTrials.gov
NCT06599216ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.